Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash from Financing Activities (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Cash from Financing Activities for 6 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 5.36% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, down 71.17% year-over-year, with the annual reading at $4.8 million for FY2025, 71.17% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $4.1 million at Caribou Biosciences, up from $277000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $322.7 million in Q3 2021, with the low at -$43000.0 in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $30.6 million, with a median of $630000.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities surged 288009.82% in 2021, then plummeted 133.86% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $460000.0 in 2021, then crashed by 72.39% to $127000.0 in 2022, then crashed by 133.86% to -$43000.0 in 2023, then skyrocketed by 9083.72% to $3.9 million in 2024, then rose by 5.36% to $4.1 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $4.1 million, $277000.0, and $6000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.